AR086100A1 - Compuestos de cromenona y composiciones farmaceuticas que los contienen - Google Patents
Compuestos de cromenona y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR086100A1 AR086100A1 ARP120101290A ARP120101290A AR086100A1 AR 086100 A1 AR086100 A1 AR 086100A1 AR P120101290 A ARP120101290 A AR P120101290A AR P120101290 A ARP120101290 A AR P120101290A AR 086100 A1 AR086100 A1 AR 086100A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- hydroxy
- optionally substituted
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para su uso en el tratamiento de trastornos de proliferación celular.Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque, en donde: R1 es alquilo C1-4 opcionalmente sustituido por hidroxi; R2 es H o alquilo C1-4; o R1y R2 juntos forman un sistema de anillo heterociclilo de 3 a 8 miembros que contiene nitrógeno que opcionalmente contiene 1 ó 2 heteroátomos adicionales que se seleccionan de oxígeno, nitrógeno y azufre, en donde un átomo de azufre del anillo opcionalmente se oxida para formar el o los S-óxidos, estando dicho anillo opcionalmente sustituido por hidroxi; R3 y R5 se seleccionan independientemente de H, halógeno, alcoxi C1-3 y ciano; R4 es H o fluoro; n es 0 ó 1 y cuando n es 1, el grupo R6 es metilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11290187 | 2011-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086100A1 true AR086100A1 (es) | 2013-11-20 |
Family
ID=46017999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101290A AR086100A1 (es) | 2011-04-13 | 2012-04-13 | Compuestos de cromenona y composiciones farmaceuticas que los contienen |
Country Status (15)
Country | Link |
---|---|
US (2) | US8530470B2 (es) |
EP (1) | EP2697220B1 (es) |
JP (1) | JP5937674B2 (es) |
KR (1) | KR101854950B1 (es) |
CN (1) | CN103596948B (es) |
AR (1) | AR086100A1 (es) |
AU (1) | AU2012241594B2 (es) |
BR (1) | BR112013026397A2 (es) |
CA (1) | CA2832787A1 (es) |
ES (1) | ES2565384T3 (es) |
HK (1) | HK1193823A1 (es) |
MX (1) | MX340300B (es) |
RU (1) | RU2598028C2 (es) |
UY (1) | UY34013A (es) |
WO (1) | WO2012140419A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9949979B2 (en) | 2011-12-15 | 2018-04-24 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
EP2653464B1 (en) * | 2012-04-20 | 2017-09-27 | Rohm and Haas Company | Benzylamine hydrophobe |
KR20150079745A (ko) | 2012-11-08 | 2015-07-08 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
WO2015146561A1 (ja) * | 2014-03-26 | 2015-10-01 | 住友精化株式会社 | 臭化芳香族エステル化合物の製造方法 |
CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
WO2017060406A1 (en) * | 2015-10-09 | 2017-04-13 | Janssen Pharmaceutica Nv | Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors |
WO2017090002A2 (en) * | 2015-11-27 | 2017-06-01 | Gvk Biosciences Private Limited | Inhibitors of pi3 kinases |
RU2612875C1 (ru) * | 2015-12-14 | 2017-03-13 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | Средство для ингибирования фермента тирозил-днк-фосфодиэстеразы 1 человека |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
RU2764522C1 (ru) * | 2021-05-25 | 2022-01-18 | Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) | 3,3'[(гексано-1,6-диилбис(азанедиил)]бис-(7-гидрокси-6-метоксикарбонил-2-оксо-2H-хромен), обладающий антибактериальной активностью |
CN113717138B (zh) * | 2021-10-21 | 2023-02-24 | 沈阳药科大学 | 一类氮芥类色原酮衍生物与应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04502322A (ja) | 1988-12-21 | 1992-04-23 | ジ・アップジョン・カンパニー | 抗アテローム性動脈硬化症性および抗血栓性1―ベンゾピラン―4―オン類および2―アミノ―1,3―ベンゾオキサジン―4―オン類 |
DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
EP1154774B1 (en) | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
RU2006124421A (ru) | 2003-12-09 | 2008-01-20 | ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) | Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения |
AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
JP5498782B2 (ja) * | 2006-06-21 | 2014-05-21 | ピラマル エンタープライジーズ リミテッド | 増殖性疾患治療用のエナンチオマー的に純粋なフラボン誘導体の調製方法 |
WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2012
- 2012-04-11 US US13/444,221 patent/US8530470B2/en not_active Expired - Fee Related
- 2012-04-11 UY UY0001034013A patent/UY34013A/es not_active Application Discontinuation
- 2012-04-12 KR KR1020137029759A patent/KR101854950B1/ko active IP Right Grant
- 2012-04-12 CN CN201280028758.5A patent/CN103596948B/zh not_active Expired - Fee Related
- 2012-04-12 RU RU2013147736/04A patent/RU2598028C2/ru not_active IP Right Cessation
- 2012-04-12 ES ES12717456.3T patent/ES2565384T3/es active Active
- 2012-04-12 EP EP12717456.3A patent/EP2697220B1/en not_active Not-in-force
- 2012-04-12 BR BR112013026397A patent/BR112013026397A2/pt not_active Application Discontinuation
- 2012-04-12 JP JP2014504388A patent/JP5937674B2/ja not_active Expired - Fee Related
- 2012-04-12 AU AU2012241594A patent/AU2012241594B2/en not_active Ceased
- 2012-04-12 CA CA2832787A patent/CA2832787A1/en not_active Abandoned
- 2012-04-12 MX MX2013011931A patent/MX340300B/es active IP Right Grant
- 2012-04-12 WO PCT/GB2012/050793 patent/WO2012140419A1/en active Application Filing
- 2012-04-13 AR ARP120101290A patent/AR086100A1/es not_active Application Discontinuation
-
2013
- 2013-08-06 US US13/960,191 patent/US20140038937A1/en not_active Abandoned
-
2014
- 2014-07-17 HK HK14107290.6A patent/HK1193823A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2598028C2 (ru) | 2016-09-20 |
ES2565384T3 (es) | 2016-04-04 |
KR20140027985A (ko) | 2014-03-07 |
RU2013147736A (ru) | 2015-05-20 |
UY34013A (es) | 2012-11-30 |
MX340300B (es) | 2016-07-05 |
HK1193823A1 (zh) | 2014-10-03 |
US20140038937A1 (en) | 2014-02-06 |
JP2014510779A (ja) | 2014-05-01 |
US8530470B2 (en) | 2013-09-10 |
CA2832787A1 (en) | 2012-10-18 |
CN103596948B (zh) | 2016-04-27 |
EP2697220B1 (en) | 2016-01-13 |
BR112013026397A2 (pt) | 2017-09-12 |
AU2012241594B2 (en) | 2016-03-10 |
WO2012140419A1 (en) | 2012-10-18 |
MX2013011931A (es) | 2014-03-27 |
CN103596948A (zh) | 2014-02-19 |
US20120264731A1 (en) | 2012-10-18 |
JP5937674B2 (ja) | 2016-06-22 |
KR101854950B1 (ko) | 2018-05-04 |
EP2697220A1 (en) | 2014-02-19 |
AU2012241594A1 (en) | 2013-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
AR078786A1 (es) | Derivados de la cromenona | |
EA201301319A1 (ru) | Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний | |
PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
MD4490B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
EA201200938A1 (ru) | Производные имидазопиридина в качестве ингибиторов jak | |
PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
EA201301209A1 (ru) | Производные пирролотриазинона в качестве ингибиторов p13k | |
EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
MA37405A1 (fr) | Composés hétérocyclyle | |
EA201201677A1 (ru) | Производные гетероарилимидазолона в качестве ингибиторов jak | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
EA201591195A1 (ru) | Новые хинолоновые производные | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
ECSP088871A (es) | Derivados de triazolopirazina | |
UY29301A1 (es) | Derivados amida | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
TN2016000014A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |